209 related articles for article (PubMed ID: 19965548)
1. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.
Wetmore JB; Liu S; Krebill R; Menard R; Quarles LD
Clin J Am Soc Nephrol; 2010 Jan; 5(1):110-6. PubMed ID: 19965548
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study.
Kim HJ; Kim H; Shin N; Na KY; Kim YL; Kim D; Chang JH; Song YR; Hwang YH; Kim YS; Ahn C; Lee J; Oh KH;
BMC Nephrol; 2013 May; 14():112. PubMed ID: 23705925
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
6. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM; Chertow GM; Parfrey PS; Kubo Y; Block GA; Correa-Rotter R; Drüeke TB; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Stolina M; Dehmel B; Goodman WG; Floege J;
Circulation; 2015 Jul; 132(1):27-39. PubMed ID: 26059012
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Wiecek A
Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
[TBL] [Abstract][Full Text] [Related]
10. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
[TBL] [Abstract][Full Text] [Related]
11. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
12. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
Reichel H; Braun J
Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
[TBL] [Abstract][Full Text] [Related]
13. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
[TBL] [Abstract][Full Text] [Related]
14. A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.
Spiegel DM; McPhatter L; Allison A; Drumheller JC; Lockridge R
Clin J Am Soc Nephrol; 2012 Apr; 7(4):632-9. PubMed ID: 22300740
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA
Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318
[TBL] [Abstract][Full Text] [Related]
19. Clinical issues regarding cinacalcet hydrochloride in Japan.
Yokoyama K
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S12-4. PubMed ID: 19765252
[TBL] [Abstract][Full Text] [Related]
20. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]